Search
-
-
Retail Prescription Drugs Filled at Pharmacies per Capita
State Health Facts Indicator -
Number of Retail Prescription Drugs Filled at Pharmacies by Payer
State Health Facts Indicator -
Retail Sales for Prescription Drugs Filled at Pharmacies by Payer
State Health Facts Indicator -
Drug Price Negotiation Doesn’t Mean the Government Will Restrict Access to Medicines
Policy WatchThis policy watch evaluates the pharmaceutical industry's claims that allowing the federal government to negotiate drug prices would restrict access to medications in Medicare. It explains what the current proposal to allow drug price negotiation would and wouldn't do.
-
Texas Emerges as Focus of New Trump Administration Actions to Limit Gender-Affirming Care
Policy WatchThis analysis explores recent actions the Trump administration has taken to limit youth access to gender-affirming care. Each has a connection to the Justice Department and to the state of Texas. These measures are widely seen as an escalation in this policy area and could add to the chilling effect already characterizing the provision of gender affirming care.
-
Mental Health and Substance Use Disorder Coverage in Medicare Advantage Plans
Issue BriefThis brief describes the scope of mental health and substance use disorder benefits in Medicare Advantage plans, including extra benefits, cost sharing, and prior authorization and referral requirements, based on an analysis of the Centers for Medicare and Medicaid Services (CMS) Medicare Advantage plan benefit and enrollment files for 2022.
-
States Expand Access to Ivermectin as Cancer Myths Continue, and Abortion Pill Faces False Water Supply Claim — The Monitor
FeatureThis volume examines unsupported claims about ivermectin; the promotion of unproven “detox” supplements in response to falsehoods about the spike protein from the COVID-19 virus and vaccine; the unsubstantiated claim that byproducts from medication abortion pills contaminate the water supply; and the renewed debate over ADHD diagnoses and treatments.
-
FAQs on Medicare Coverage and Costs Related to COVID-19 Testing and Treatment
Issue BriefThese FAQs provide the latest guidance on testing and treatment related to COVID-19 for Medicare beneficiaries, including questions related to out-of-pocket costs, the COVID-19 vaccine, telehealth, extended supplies of medication, skilled nursing facility stays, and issues for people in private Medicare Advantage plans.
-
How Many Adults with Private Health Insurance Could Use GLP-1 Drugs
Issue BriefMore than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis. Though only about 3% of adults with employer coverage had a prescription in 2022, demand for and spending on GLP-1 drugs has grown and could continue to grow. Given…